Skip to content

Study · In vitro (cells) · 2011

3 results

Neuroprotective and nootropic drug noopept rescues α-synuclein amyloid cytotoxicity.

Jia X, Gharibyan AL, Öhman A, Liu Y, Olofsson A, Morozova-Roche LA

Journal of molecular biology1 Oct 2011Cited by 11 (Europe PMC)

PMID21986202 (opens in a new tab)DOI10.1016/j.jmb.2011.09.044 (opens in a new tab)PepBankPUB-21986202
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Efficacy outcome

    In SH-SY5Y cells, Noopept's sequestration of amyloid oligomers reduced their cytotoxic effect.

    In plain wordsIn cells, Noopept reduced toxic effects from amyloid clusters.

    Peptide
    Noopept (omberacetam)
    Outcome
    DecreaseAmyloid oligomer cytotoxicity
    Study

    n: not reported in source

    Neuroblastoma SH-SY5Y cells exposed to amyloid oligomers
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Consequently, this process rescues the cytotoxic effect of amyloid oligomers on neuroblastoma SH-SY5Y cells as demonstrated by using cell viability assays and fluorescent staining of apoptotic and necrotic cells and by assessing the level of intracellular oxidative stress.
    1 context sentence
    Summary · context
    Noopept does not bind to a sterically specific site in the α-Syn molecule as revealed by heteronuclear two-dimensional NMR analysis, but due to hydrophobic interactions with toxic amyloid oligomers, it prompts their rapid sequestration into larger fibrillar amyloid aggregates.
  2. 02LabIn vitro (cell-free)Mechanism

    In molecular tests, Noopept did not bind a sterically specific site in alpha-synuclein.

    In plain wordsIn lab tests, Noopept did not bind a specific site on alpha-synuclein.

    Peptide
    Noopept (omberacetam)
    Outcome
    No significant changeBinding to a specific alpha-synuclein site
    Study

    n: not reported in source

    Alpha-synuclein molecules
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Noopept does not bind to a sterically specific site in the α-Syn molecule as revealed by heteronuclear two-dimensional NMR analysis
  3. 03LabIn vitro (cell-free)Mechanism

    In molecular tests, Noopept promoted rapid sequestration of toxic alpha-synuclein oligomers into larger fibrillar aggregates through hydrophobic interactions.

    In plain wordsIn lab tests, Noopept promoted the collection of toxic alpha-synuclein clusters into larger fibers through hydrophobic interactions.

    Peptide
    Noopept (omberacetam)
    Outcome
    IncreaseSequestration into larger fibrillar aggregates
    Study

    n: not reported in source

    Alpha-synuclein amyloid oligomers
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    but due to hydrophobic interactions with toxic amyloid oligomers, it prompts their rapid sequestration into larger fibrillar amyloid aggregates.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.